Dynavax Technologies (NASDAQ:DVAX) Lowered to “Hold” at StockNews.com

StockNews.com lowered shares of Dynavax Technologies (NASDAQ:DVAX) from a buy rating to a hold rating in a report issued on Friday morning.

Other research analysts have also issued research reports about the company. William Blair reissued an outperform rating on shares of Dynavax Technologies in a report on Friday, February 23rd. The Goldman Sachs Group started coverage on Dynavax Technologies in a research report on Thursday, February 1st. They set a neutral rating and a $20.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of Moderate Buy and an average target price of $25.00.

Dynavax Technologies Trading Up 0.4 %

NASDAQ:DVAX opened at $11.21 on Friday. Dynavax Technologies has a 52-week low of $10.06 and a 52-week high of $15.15. The stock has a fifty day moving average of $12.23 and a 200 day moving average of $13.19. The company has a debt-to-equity ratio of 0.41, a current ratio of 13.81 and a quick ratio of 12.96.

Insiders Place Their Bets

In other Dynavax Technologies news, CAO Justin Burgess sold 20,526 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $12.78, for a total transaction of $262,322.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 2.98% of the company’s stock.

Institutional Investors Weigh In On Dynavax Technologies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BluePath Capital Management LLC purchased a new stake in shares of Dynavax Technologies in the third quarter worth about $33,000. DekaBank Deutsche Girozentrale purchased a new stake in Dynavax Technologies in the 3rd quarter worth approximately $33,000. Advisor Resource Council acquired a new stake in shares of Dynavax Technologies during the 4th quarter worth approximately $144,000. Rathbones Group PLC purchased a new position in shares of Dynavax Technologies during the 3rd quarter valued at approximately $158,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in shares of Dynavax Technologies in the 4th quarter valued at $209,000. 96.96% of the stock is owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.